Publication:
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01-AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens

dc.contributor.authorTorsak Bunupuradahen_US
dc.contributor.authorJintanat Ananworanichen_US
dc.contributor.authorPloenchan Chetchotisakden_US
dc.contributor.authorPacharee Kantipongen_US
dc.contributor.authorSupunnee Jirajariyavejen_US
dc.contributor.authorSunee Sirivichayakulen_US
dc.contributor.authorWarangkana Munsakulen_US
dc.contributor.authorWisit Prasithsirikulen_US
dc.contributor.authorSomnuek Sungkanuparphen_US
dc.contributor.authorChureeratana Bowonwattanuwongen_US
dc.contributor.authorVirat Klinbuayaemen_US
dc.contributor.authorKathy Petoumenosen_US
dc.contributor.authorBernard Hirschelen_US
dc.contributor.authorSorakij Bhakeecheepen_US
dc.contributor.authorKiat Ruxrungthamen_US
dc.contributor.otherThe HIV Netherlands Australia Thailand Research Collaborationen_US
dc.contributor.otherUniversity of New South Wales (UNSW) Australiaen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherSEARCHen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherChiangrai Prachanukroh Hospitalen_US
dc.contributor.otherTaksin Hospitalen_US
dc.contributor.otherVajira Hospitalen_US
dc.contributor.otherBamrasnaradura Infectious Disease Instituteen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherChonburi Regional Hospitalen_US
dc.contributor.otherSanpatong Hospitalen_US
dc.contributor.otherUniversite de Geneveen_US
dc.contributor.otherNational Health Security Officeen_US
dc.date.accessioned2018-05-03T08:23:09Z
dc.date.available2018-05-03T08:23:09Z
dc.date.issued2011-11-03en_US
dc.description.abstractBackground: We studied prevalence of etravirine (ETR) and rilpivirine (RPV) resistance in HIV-1 subtype CRF01-AE infection with first-line non-nucleoside reverse transcriptase inhibitor (NNRTI) failure. Methods: A total of 225 adults failing two nucleoside reverse transcriptase inhibitors (NRTIs) plus 1 NNRTI in Thailand with HIV RNA > 1,000 copies/ml were included. Genotypic resistance results and HIV-1 subtype were interpreted by Stanford DR database. ETR resistance was calculated by the new Monogram weighted score (Monogram WS; ≥4 indicating high-level ETR resistance) and by DUET weighted score (DUET WS; 2.5-3.5 and ≥4 resulted in intermediate and reduce ETR response, respectively). RPV resistance interpretation was based on previous reports. Results: Median (IQR) age was 38 (34-42) years, 41% were female and CDC A:B:C were 22%:21%:57%. HIV subtypes were 96% CRF01-AE and 4% B. Antiretrovirals at failure were lamivudine (100%), stavudine (93%), nevirapine (90%) and efavirenz (10%) with a median (IQR) duration of 3.4 (1.8-4.5) years. Median (IQR) CD4 + T-cell count and HIV RNA were 194 (121-280) cells/mm 3 and 4.1 (3.6-4.6) log 10 copies/ml, respectively. The common NNRTI mutations were Y181C (41%), G190A (22%) and K103N (19%). The proportion of patients with Monogram WS score ≥4 was 61.3%. By DUET WS, 49.8% and 7.5% of patients were scored 2.5-3.5 and ≥4, respectively. Only HIV RNA≥4 log 10 copies/ml at failure was associated with both Monogram WS≥4 (OR 2.3, 95% CI 1.3-3.9; P=0.003) and DUET WS≥2.5 (OR 1.9, 95% CI 1.1-3.3; P=0.02). The RVP resistance-associated mutations (RAMs) detected were K101P (1.8%), Y181I (2.7%) and Y181V (3.6%). All patients with RPV mutation had ETR resistance. No E138R/E138K mutations were detected. Conclusions: Approximately 60% of patients had highlevel ETR resistance. The role of ETR in second-line therapy is limited in late NNRTI failure settings. RVP RAMs were uncommon, but cross-resistance between ETR and RVP was high. ©2011 International Medical Press.en_US
dc.identifier.citationAntiviral Therapy. Vol.16, No.7 (2011), 1113-1121en_US
dc.identifier.doi10.3851/IMP1906en_US
dc.identifier.issn13596535en_US
dc.identifier.other2-s2.0-80055099715en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/12225
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80055099715&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleEtravirine and rilpivirine resistance in HIV-1 subtype CRF01-AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimensen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80055099715&origin=inwarden_US

Files

Collections